publication date: Jan. 17, 2020

NCI increases funding for extramural research by $210M in FY2020; funds more than 125 additional competing awards

By Matthew Bin Han Ong

With a budgetary increase of $297 million in FY2020, NCI anticipates funding more than 125 additional competing awards over FY19 levels—and devoting more than $210 million in new funding to support extramural research and training opportunities.

The budget increase allows NCI to boost paylines across different award types. For instance, the paylines for R01 grants are going up by 25%, moving from the 8th percentile in FY19 to the 10th percentile in FY20. This is the first time NCI has been able to afford double-digit paylines for R01 grants since 2017.

“We are profoundly grateful to the many champions of people with cancer and survivors, as well as supporters of cancer research in Congress, especially the leaders of the House and Senate appropriations committees who are primarily responsible for approving the NCI budget,” NCI Director Ned Sharpless wrote in a Jan. 16 blog post. “NCI welcomes the budget increase as an opportunity to advance progress against cancer and to ensure that the oncology tools of tomorrow are more powerful than those we have today.”

The latest bump in appropriations also allows NCI to restore noncompeting grants at the institute to 100%.

“Under our temporary grant policies for the CR, NCI was funding most non-competing grants at 90%,” Sharpless wrote. “With our new budget in hand, NCI will now pay non-competing grants at 100%. And, as soon as possible, we will revise awards for any non-competing grants we issued since October 1, 2019, to the 100% level. Of note, last year we were only able to support … Continue reading NCI increases funding for extramural research by $210M in FY2020; funds more than 125 additional competing awards

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.